medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 2

<< Back Next >>

Med Int Mex 2023; 39 (2)

Hyperleukocytosis as paraneoplastic syndrome of pulmonary sarcomatoid giant cell carcinoma

Ibarra-Montiel K, Nava-Gutiérrez W, Carrizales-Villarreal JA

Language: Spanish
References: 27
Page: 386-392
PDF size: 243.33 Kb.


ABSTRACT

Background: Sarcomatoid lung carcinoma is a poorly differentiated malignant tumor, which is reported only in the form of clinical cases. Even though hematological alterations are frequent in patients with cancer, only a couple of cases of hyperleukocytosis have been described in this type of cancer, associated with greater aggressiveness and poor prognosis.
Clinical case: A 58-year-old male patient with a history of environmental exposure to organic and inorganic dusts, as well as a high-risk smoking index, with persistent cough, associated with wasting syndrome; the chest tomography showed an image suggestive of a mediastinal tumor, and the laboratory findings showed hyperleukocytosis, suspecting hematological neoplasia; the histopathological study confirmed a tumor of pulmonary origin.
Conclusions: The presentation of an unusual paraneoplastic syndrome in the evolution of a very rare histological lineage lung tumor leads to confusion in the approach and a delay in the diagnosis and definitive treatment.


REFERENCES

  1. Kristin Henry. Paraneoplastic syndromes: Definitions,classification, pathophysiology and principals of treatment.Semin Diagn Pathol 2019; 36 (4): 204-210. doi: 0.1053/j.semdp.2019.01.002.

  2. Richardson GE, Johnson BE. Paraneoplastic syndromesin lung cancer. Curr Opin Oncol 1992; 4 (2): 323-33. doi:10.1097/00001622-199204000-00014.

  3. Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, IshiiT, Dobashi H, Matsunaga T. Paraneoplastic syndromesassociated with lung cancer. World J Clin Oncol 2014; 5(3): 197-223. doi: 10.21037/atm.2019.04.86.

  4. Sakka V, Tsiodras S, Giamarellos-Bourboulis EJ, GiamarellouH. An update on the etiology and diagnostic evaluation of aleukemoid reaction. Eur J Intern Med 2006; 17 (6): 394-8.doi: 10.1016/j.ejim.2006.04.004.

  5. Riesenberg H, Müller F, Görner M. Leukemoid reaction ina patient with adenocarcinoma of the lung: a case report.J Med Case Rep 2012; 6: 211. doi: 10.1186/1752-1947-

  6. 6-211.6. Wang D, Zhang H, Yu F, Fang B. Extreme leukocytosis andleukemoid reaction associated with the lung sarcomatoidcarcinoma: an unusual case report. Int J Gen Med 2016;10: 7-9. https://doi.org/10.2147/IJGM.S102524.

  7. Marouf A, Chapuis N, Alary AS, Burroni B, Kosmider O,Alifano M, Bouscary D, Paraneoplastic hyperleukocytosismimicking hematologic malignancy revealing a localizedlung cancer. Ann Thoracic Surg 2019. doi: https://doi.org/10.1016/j.athoracsur.2019.06.064.

  8. Shinki Konyama, Shigeki Sugiyama, Yoshinori Toki, TakuroMisaki, Kazuhiro Matsui, Masanobu Kitagawa. A case ofgiant cell lung cancer with leukocytosis. Lung Cancer 1996;36 (1): 41-47. https://doi.org/10.2482/haigan.36.41.

  9. Sreevatsa A, Babu SM, Babu GK, Suresh TM. Hyperleukocytosis,an unusual paraneoplastic manifestation of lungcancer: Case report and review of literature. J Can Res Ther2015; 11: 669. doi: 10.4103/0973-1482.151865.

  10. WHO. Who report on cancer: setting priorities, investingwisely and providing care for all. World Health Organization,2020: 160.

  11. Travis WD, Brambilla E, Burke AP, Marx A, et al. WHOClassification of Tumours of the Lung, Pleura, Thymus andHeart, Lyon, France: International Agency for Research onCancer; 2015; 7: 412.

  12. Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, GreilR, et al. Longitudinal analysis of 2293 NSCLC patients: Acomprehensive study from the TYROL registry. Lung Cancer2015; 87 (2): 193-200. http://dx.doi.org/10.1016/j.lungcan.2014.12.006.

  13. Li X, Zhang Z, Liu J, Wang D, Wei S, Chen J. Molecularfeatures of giant-cell carcinoma of the lung: a case reportand literature review. OncoTargets Ther 2018; 11: 751-756.https://doi.org/10.2147/OTT.S150124.

  14. Anwar A, Jafri F, Ashraf S, Jafri MAS, Fanucchi M. Paraneoplasticsyndromes in lung cancer and their management.Ann Transl Med 2019; 7 (15): 359-359. doi: 10.21037/atm.2019.04.86.

  15. Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG,Najjar M, Pfeiffer C. Hematological and iron-relatedanalytes-reference data for persons aged 1 year andover: United States, 1988-94. Vital Heal Stat 11 2005;11 (247): 1-156.

  16. Granger JM, Kontoyiannis DP. Etiology and outcome of extremeleukocytosis in 758 nonhematologic cancer patients:A retrospective, single-institution study. Cancer 2009; 115(17): 3919-23. doi: 10.1002/cncr.24480.

  17. I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K.Tumor-related leukocytosis is linked with poor prognosis inpatients with lung carcinoma. Cancer 2001; 92 (9): 2399-405. doi: 10.1002/1097-0142(20011101)92:9<2399::aidcncr1588>3.0.co;2-w.

  18. Polymeris A, Kogia C, Ioannidis Di, Lilis Di, Drakou M, MaounisN, et al. Excessive leukocytosis leading to a diagnosisof aggressive thyroid anaplastic carcinoma: A Case reportand relevant review. Eur Thyroid J 2020; 9 (3): 162-8. doi:10.1159/000506767.

  19. Dorn C, Bugl S, Malenke E, Müller MR, Weisel KC, Vogel U,et al. Paraneoplastic granulocyte colony-stimulating factorsecretion in soft tissue sarcoma mimicking myeloproliferativeneoplasia: A case report. BMC Res Notes 2014; 7 (1):3-7. doi: 10.1186/1756-0500-7-313.

  20. Asano S, Urabe A, Okabe T, Sato N, Kondo Y. Demonstrationof granulopoietic factor(s) in the plasma of nude micetransplanted with a human lung cancer and in the tumortissue. Blood 1977; 49 (5): 845-52.

  21. Shimasaki AK, Hirata K, Kawamura T, Kunibe N, Hirai K,Yoshimoto K, et al. ORIGINAL ARTICLE Shimasaki. 1992;31 (7): 861-5.

  22. Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU,Kurzrock R. Granulocyte-macrophage colony-stimulatingfactor as a cause of paraneoplastic leukaemoid reaction inadvanced transitional cell carcinoma. J Intern Med 1993;

  23. 234 (4): 417-20. doi: 10.1111/j.1365-2796.1993.tb00765.x.23. Ma X, Li G, Cai Z, Sun W, Liu J, Zhang F. Leukemoid reactionin malignant bone tumor patients - A retrospective,single-institution study. Eur Rev Med Pharmacol Sci 2012;16 (14): 1895-9.

  24. Shalom G, Sion-Vardy N, Dudnik J, Ariad S. Leukemoidreaction in lung cancer patients. Isr Med Assoc J 2010;12 (4): 255-6.

  25. Ruggiero A, Rizzo D, Amato M, Riccardi R. Management ofhyperleukocytosis. Curr Treat Options Oncol 2016; 17 (2):1-10. doi: 10.1007/s11864-015-0387-8.

  26. Porcu P, Farag S, Marcucci G, Cataland SR, KennedyMS, Bissell M. Leukocyto-reduction for acute leukemia.Ther Apher 2002; 6 (1): 15-23. doi: 10.1046/j.1526-0968.2002.00402.x.

  27. Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, BarataF, Park K, Popat S, Bergman B, Parente B, Gallo C, GridelliC, Perrone F, Di Maio M. Six versus fewer planned cycles offirst-line platinum-based chemotherapy for non-small-celllung cancer: a systematic review and meta-analysis of individualpatient data. Lancet Oncol 2014; 15 (11): 1254-62.doi: 10.1016/S1470-2045(14)70402-4.




2020     |     www.medigraphic.com